This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

  Mobile version   RSS   Subscribe   Unsubscribe   Archive   Media Kit Nov. 6, 2013


FDA asks manufacturer of leukemia drug Iclusig (ponatinib) to suspend marketing and sales
The U.S. Food and Drug Administration (FDA) has asked the manufacturer of the leukemia chemotherapy drug Iclusig (ponatinib) to suspend marketing and sales of Iclusig because of the risk of life-threatening blood clots and severe narrowing of blood vessels. [The FDA] will continue to evaluate the drug to further understand its risks and potential patient populations in which the benefits of the drug may outweigh the risks. Patients currently receiving Iclusig should discuss with their health care professionals the risks and benefits of continuing treatment with the drug.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


BRAF status not associated with negative predictors for papillary thyroid cancer
BRAFV600E mutations were not significantly associated with most clinicopathologic features suggestive of aggressive papillary thyroid carcinoma, according to results of a retrospective study. Researchers pooled data on 429 patients from the pathology archives at the University of California to assess the significance of BRAF V600E mutation in papillary thyroid cancer. Clinicopathologic features in patients with and without BRAF mutations served as the primary outcome measure.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Newly identified biomarkers promise earlier, less invasive colon cancer detection
Medical Daily
A new study stands to transform screening protocols and prevention strategies against colorectal cancer. Scientists at the Research Institute of the McGill University Health Centre in Canada have discovered genetic variations in the colon lining in colorectal cancer patients that may be used to synthesize new biomarkers for tumor growth. The findings could help oncologists replace biopsies and subjective evaluations with new, minimally-invasive screening measures.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  What You Wish Your Peers Would Share With You.
One hour now will save you three years of anxiety. This webinar will cover topics from Fee for Value to the type of IT capabilities you will need to be successful within the Affordable Care Act.
November 12, 2013
Two convenient times – 11 AM Central and then 11 AM Pacific.
Click here to choose your time and register.

Liver cancer progenitor cells identified before tumors can be detected
Oncology Nurse Advisor
Researchers have isolated and characterized the progenitor cells that give rise to malignant hepatocellular carcinoma tumors long before the actual tumors can be detected. These results may have profound implications for the diagnosis and treatment of hepatocellular carcinoma, the most common form of liver cancer. An estimated 30,000 new cases of liver cancer are diagnosed annually in the United States, mostly in men. More than 21,600 Americans die from liver cancer each year and that rate has doubled over the past 20 years. Hepatocellular carcinoma is the third leading cause of cancer-related deaths worldwide.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Gene responsible for hereditary cancer syndrome found to disrupt critical growth-regulating pathway
Medical Xpress
Whitehead Institute scientists report that the gene mutated in the rare hereditary disorder known as Birt-Hogg-Dubé cancer syndrome also prevents activation of mTORC1, a critical nutrient-sensing and growth-regulating cellular pathway. This is an unexpected finding, as some cancers keep this pathway turned on to fuel their unchecked growth and expansion. In the case of Birt-Hogg-Dubé syndrome, the mutated gene prevents mTORC1 pathway activation early in the formation of tumors.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

NAPBC education event — Lead Your Breast Program to Excellence
Plan today to attend the National Accreditation Program for Breast Centers (NAPBC) Lead Your Breast Program to Excellence Conference. This dynamic, two-day conference will include expert faculty who developed the standards. Hear how you can build quality programs into your multidisciplinary breast center by utilizing nationally recognized standards as your foundation. This two-day conference will be held Nov. 15–16 in Chicago. Last year’s program was sold out; don’t delay, registration is already filling up. Register TODAY!
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

1 dose of HPV vaccine may be enough to prevent cervical cancer
Science Codex
Women vaccinated with one dose of a human papillomavirus (HPV) vaccine had antibodies against the viruses that remained stable in their blood for four years, suggesting that a single dose of vaccine may be sufficient to generate long-term immune responses and protection against new HPV infections, and ultimately cervical cancer, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Oncology OnTrack Supports Nurse Navigation
Oncology OnTrack is used to navigate patients with any cancer type from screening to diagnosis, treatment and survivorship, interfaces with other programs and supports accreditations.
EQUICARE CS - Cancer Navigation and Survivorship

EQUICARE CS provides all three facets of continuum of care services and has included information on their services in the Proprietary Material section of the Best Practices Repository section on the CoC website.

Brain tumor drug IDs cancer cells from healthy ones
Drug Discovery & Development
A potential new drug, already in clinical development, can stop brain tumor cells growing while leaving healthy cells alone, according to new research published in PLOS ONE. Cancer Research U.K. scientists from the Samantha Dickson Brain Cancer Unit, which is funded by The Brian Tumor Charity, at the UCL Cancer Institute in London focused on glioblastoma, the most common type of brain tumor. Using cells growing in the lab, they treated glioblastoma cells and healthy cells with more than 150 potential drugs, and compared the responses. One of these molecules, called J101, was able to stop the cancer cells growing but left the normal cells alone.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
Looking for similar articles? Search here, keyword BRAIN TUMOR.

Help us improve AJCC cancer staging resources!
The AJCC has commissioned a survey to solicit user feedback on the AJCC Cancer Staging Manual, Handbook, and Atlas. The AJCC will use this information to enhance current and future products.

After just 10 minutes of their time, all participants will be entered into a raffle for the chance to win one of ten $100 American Express gift cards. Click HERE to take the survey.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Why tumor cells go on dangerous tours
Science Codex
Tumors become highly malignant when they acquire the ability to colonize other tissues and form metastases. Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich have identified a factor that promotes metastasis of colon tumors — and presents a possible target for therapy. The protein c-MYC is referred to as a master regulator because it controls the activity of hundreds of genes, including many that drive cell growth and cell proliferation. Genetic changes that perturb its own regulation therefore have serious consequences for tissue homeostasis, and often result in cancer. Indeed, in most cancers, one finds mutations that hyperactivate the c-MYC gene.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Decoding breast cancer drug resistance
The Scientist
Estrogen is so intimately involved in breast cancer that drugs which disrupt the hormone’s actions have become frontline treatments for the disease. These so-called “hormonal therapies” include tamoxifen and fulvestrant, which directly block the estrogen receptor, and aromatase inhibitors like anastrazole, which prevent the body from making estrogen in the first place. These drugs have been incredibly successful, but for reasons that are still unclear, patients often develop resistance to them, especially when their tumors migrate, or metastasize, to other organs.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

The CoC Brief

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Samantha Emerson, Content Editor, 469.420.2669
Contribute news

Disclaimer: The CoC Brief is a digest of the most important news selected for the American College of Surgeons Commission on Cancer from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The Commission on Cancer does not endorse any of the advertised products and services. Opinions expressed in the articles are those of the author and not of the American College of Surgeons and the Commission on Cancer.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of The CoC Brief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Oct. 30, 2013
Oct. 24, 2013
Oct. 23, 2013
Oct. 18, 2013

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063